Karen Corallo

9/9/2021  /  Criminal Investigations , Deferred Prosecution Agreements , Department of Justice (DOJ) , Enforcement Actions , False Claims Act (FCA) , Falsified Documents , Federal Food Drug and Cosmetic Act (FFDCA) , Food and Drug Administration (FDA) , Manufacturers , Medical Devices , Product Defects , Qui Tam , Whistleblowers

8/18/2021  /  Department of Justice (DOJ) , False Claims Act (FCA) , Federal Food Drug and Cosmetic Act (FFDCA) , Fifth Amendment , Final Rules , First Amendment , Food and Drug Administration (FDA) , Intended Use , Life Sciences , Manufacturers , Medical Devices , Off-Label Use , Pharmaceutical Industry , Product Labels , Safe Harbors

11/25/2020  /  Coronavirus/COVID-19 , Corporate Integrity Agreement , Department of Health and Human Services (HHS) , Department of Justice (DOJ) , Fraud Alerts , Health Care Providers , Healthcare Fraud , Life Sciences , OIG , Pharmaceutical Industry , Speaker Programs

7/15/2020  /  Coronavirus/COVID-19 , Domestic Corporations , Food and Drug Administration (FDA) , Foreign Corporations , Medical Devices , Pharmaceutical Industry , Prescription Drugs , Public Health , Rating System , Re-Opening Guidelines , Risk Assessment , Safety Inspections , Tobacco Regulations

6/11/2020  /  Coronavirus/COVID-19 , Drug Distribution , Food and Drug Administration (FDA) , Pharmaceutical Industry , Pharmacies , Prescription Drugs , Supply Chain

4/30/2020  /  Civil Monetary Penalty , Clinical Laboratory Testing , Compliance , Coronavirus/COVID-19 , Corporate Misconduct , Criminal Penalties , Criminal Prosecution , Department of Justice (DOJ) , Enforcement Actions , False Advertising , False Claims Act (FCA) , Federal Prosecutors , Health IT , Inducements , Kickbacks , Life Sciences , Medical Devices , Medical Technology Companies , Off-Label Promotion , Patient Safety , Pharmaceutical Industry , Product Defects , Sunshine Act

3/5/2020  /  Acquisitions , Anti-Discrimination Policies , Business Interruption , Capital Markets , Centers for Disease Control and Prevention (CDC) , Commercial Contracts , Coronavirus/COVID-19 , Corporate Restructuring , Cybersecurity , Derivatives , Disclosure Requirements , Employment Policies , Equity Securities , Force Majeure Clause , Global Economy , Leveraged Finance , Life Sciences , Mergers , OSHA , Popular , Public Health , Public Safety , Publicly-Traded Companies , Securities and Exchange Commission (SEC) , Securities Litigation , Supply Chain , Virtual Meetings

1/30/2020  /  Acquisitions , Administrative Procedure Act , Anti-Discrimination Policies , Anti-Harassment Policies , Anti-Kickback Statute , Antitrust Investigations , Appeals , Arbitration Awards , Attorney General , Backstop Agreements , BEPS , BitLicense , Blockchain , Board of Directors , Bonds , Capital Markets , CFIUS , CFTC , Chapter 11 , Claim Preclusion , Class Action , Commercial Bankruptcy , Common Stock , Congressional Investigations & Hearings , Congressional Subpoenas , Consumer Financial Protection Bureau (CFPB) , Cooperation Agreement , Copyright , Corporate Governance , Corporate Restructuring , Corporate Social Responsibility , Corporate Taxes , Corwin Doctrine , Covenant Lite Deals , Creditors , Cross-Border Transactions , DACA , DE Supreme Court , Debt Financing , Debtors , Department of Justice (DOJ) , Dischargeable Debts , Disgorgement , Disparate Impact , Dodd-Frank , Down Rounds , Drug Pricing , EBITDA , Employee Retirement Income Security Act (ERISA) , Employer Liability Issues , Employment Discrimination , Enforcement Actions , Enforcement of Foreign Judgments , Enterprise Act 2002 , Environmental Social & Governance (ESG) , EU , Fair Housing Act (FHA) , Federal Trade Commission (FTC) , FinTech , FIRRMA , Foreign Acquisitions , Foreign Investment , Foreign Issuers , FRCP 23 , General Data Protection Regulation (GDPR) , General Elections , GILTI tax , High-Yield Markets , Hong Kong , Hong Kong Stock Exchange , Individual Accountability , Initial Public Offering (IPO) , Intellectual Property Litigation , Intercreditor Agreements , International Arbitration , International Litigation , IRS , Issue Preclusion , Japan , Joint Venture , Legislative Agendas , Life Sciences , Listing Rules , Litigation Strategies , Make-Whole Premium , Mergers , MFW , Multinationals , National Security , PCAOB , Pharmaceutical Industry , Political Parties , Preferred Shares , Private Offerings , Privately Held Corporations , Proxy Advisory Firms , Publicly-Traded Companies , Refinancing , Regulatory Agenda , Reporting Requirements , SCOTUS , Securities and Exchange Commission (SEC) , Securities Litigation , Separation of Powers , Shareholder Activism , Shareholder Proposals , Shareholders , Split of Authority , State Labor Laws , Stock Drop Litigation , Tax Cuts and Jobs Act , Tax Litigation , Technology Sector , Third-Party Release Agrements , Transparency , UK , UK Brexit , Valuation , White Collar Crimes

1/24/2020  /  Anti-Kickback Statute , Data Privacy , Department of Health and Human Services (HHS) , Department of Justice (DOJ) , Drug Pricing , Enforcement Actions , False Claims Act (FCA) , Food and Drug Administration (FDA) , Fraud , Fraud and Abuse , Health Care Providers , Health Insurance Portability and Accountability Act (HIPAA) , Healthcare Costs , Imports , Innovation , Legislative Agendas , Life Sciences , Medical Devices , Medicare Part D , Pharmaceutical Industry , PHI , Prescription Drugs , Proposed Legislation , Settlement Agreements , State Legislatures , Trump Administration

12/2/2019  /  Anti-Kickback Statute , Big Data , CDRH , Charitable Organizations , Co-payments , Data Privacy , Department of Justice (DOJ) , Dietary Supplements , Disgorgement , Drug Pricing , Enforcement Actions , False Advertising , False Claims Act (FCA) , Federal Food Drug and Cosmetic Act (FFDCA) , Federal Trade Commission (FTC) , Food and Drug Administration (FDA) , Food Manufacturers , Health Insurance Portability and Accountability Act (HIPAA) , Lanham Act , Life Sciences , Medical Devices , NAD , Off-Label Promotion , OIG , OPDP , Pharmaceutical Industry , Physician Compensation Arrangements , Pleading Standards , POM Wonderful v Coca Cola , REMS , RICO , Risk Assessment , Risk Management , SCOTUS , Tobacco